Jayastu Senapati

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Elias Jabbour, Nicholas J. Short, Jayastu Senapati et al. · The Lancet Haematology · 2023 · 98 citations · Full text

Inotuzumab Ozogamicin, Lymphoid Neoplasia, Hematological Malignancy +9

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Nitin Jain, Jayastu Senapati, Beenu Thakral et al. · Blood Advances · 2022 · 72 citations · Full text

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti et al. · Blood · 2022 · 62 citations

Hematological Malignancy, Oncology, Phase I/ii Study +6

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Jayastu Senapati, Samuel Urrutia, Sanam Loghavi et al. · Blood · 2023 · 58 citations

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet et al. · Blood · 2022 · 54 citations · Full text